Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 24,375 shares, an increase of 96.7% from the July 30th total of 12,389 shares. Based on an average trading volume of 152,801 shares, the short-interest ratio is currently 0.2 days. Currently, 2.6% of the shares of the stock are short sold.

Curanex Pharmaceuticals Stock Performance

Shares of CURX opened at $4.30 on Tuesday. Curanex Pharmaceuticals has a 52 week low of $3.58 and a 52 week high of $183.59. The stock has a market capitalization of $6.74 million and a price-to-earnings ratio of -0.55. The stock has a fifty day moving average of $4.47 and a 200-day moving average of $6.54.

Curanex Pharmaceuticals (NASDAQ:CURX) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.40) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Curanex Pharmaceuticals has a consensus rating of “Sell”.

Institutional Investors Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.